belatacept

{{Short description|Pharmaceutical drug}}

{{Drugbox

| Verifiedfields = changed

| verifiedrevid = 447616853

| image =

| alt =

| pronounce =

| tradename = Nulojix

| Drugs.com = {{drugs.com|monograph|belatacept}}

| MedlinePlus = a606016

| licence_EU = yes

| DailyMedID = Belatacept

| licence_US = Belatacept

| pregnancy_AU = C

| pregnancy_US = N

| pregnancy_category =

| routes_of_administration = Intravenous

| ATC_prefix = L04

| ATC_suffix = AA28

| legal_AU = S4

| legal_CA =

| legal_UK = POM

| legal_US = Rx-only

| legal_EU = Rx-only

| legal_status =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number_Ref = {{cascite|correct|CAS}}

| CAS_number = 706808-37-9

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank = DB06681

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = None

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = E3B2GI648A

| KEGG = D03222

| chemical_formula =

| molecular_weight =

}}

Belatacept, sold under the brand name Nulojix, is a fusion protein composed of the Fc fragment of a human IgG1 immunoglobulin linked to the extracellular domain of CTLA-4,{{cite web |url=http://www.healthvalue.net/ctlaigenglish.html |title=Healthvalue.net: CTLA-4 Strategies|access-date=2008-10-24| archive-url= https://web.archive.org/web/20081205034856/http://www.healthvalue.net/ctlaigenglish.html| archive-date= 5 December 2008 | url-status= live}} which is a molecule crucial in the regulation of T cell costimulation, selectively blocking the process of T-cell activation. It is intended to provide extended graft and transplant

{{cite journal | vauthors = Vincenti F, Rostaing L, Grinyo J, Rice K, Steinberg S, Gaite L, Moal MC, Mondragon-Ramirez GA, Kothari J, Polinsky MS, Meier-Kriesche HU, Munier S, Larsen CP | display-authors = 6 | title = Belatacept and Long-Term Outcomes in Kidney Transplantation | journal = The New England Journal of Medicine | volume = 374 | issue = 4 | pages = 333–43 | date = January 2016 | pmid = 26816011 | doi = 10.1056/NEJMoa1506027 | hdl = 2445/178537 | s2cid = 35661528 | hdl-access = free }}

survival while limiting the toxicity generated by standard immune suppressing regimens, such as calcineurin inhibitors. It differs from abatacept (Orencia) by only two amino acids.{{medcn|date=December 2020}}

Belatacept was developed by Bristol-Myers-Squibb and approved by the U.S. Food and Drug Administration (FDA) on June 15, 2011.{{cite press release |url=https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm259184.htm |title=FDA approves Nulojix for kidney transplant patients |publisher=U.S. Food and Drug Administration |date=2011-06-15 |access-date=2011-06-16| archive-url= https://web.archive.org/web/20110619051309/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm259184.htm| archive-date= 19 June 2011 | url-status= dead}}